If you have been reading about Dihexa and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
"Victims as Defenders: African Troops in the Rhodesian Defence System 1890–1980". Small Wars & Insurgencies. 2 (2): 240–275. doi:10.1080/09592319108422981. Molomo, Mpho G. (2009). "The Link between Sustainable Development and Security in Botswana". In Cawthra, Gavin (ed.). African Security Governance: Emerging Issues. Tokyo: United Nations University Press. pp. 131–156. ISBN 9789280811773. Melson, C. D. (2005). "Top Secret War: Rhodesian Special Operations". Small Wars and Insurgencies. 16 (1): 57–82. doi:10.1080/0959231042000322567. S2CID 145455177. Moorcraft, Paul L.; McLaughlin, Peter (1982). Chimurenga! The War in Rhodesia, 1965-1980. A Military history. Marshalltown, South Africa: Sygma/Collins. ISBN 0620062142. Moorcraft, P. L.; McLaughlin, P. (2010). The Rhodesian War: A Military History. Stackpole Books. ISBN 9780811707251. Morse, Stephen A. (2006). "Historical Perspectives of Microbial Bioterrorism". In Anderson, Burt; Friedman, Herman; Bendinelli, Mauro (eds.). Microorganisms and Bioterrorism. New York City: Springer. pp. 15–30. ISBN 9780387281568. O'Brien, Kevin (September 2001). "Counter-Intelligence for counter-revolutionary warfare: The South African police security branch 1979–1990". Intelligence and National Security. 16 (3): 27–59. doi:10.1080/02684520412331306200. S2CID 153561623. Palmer, Robin (October 1983). "Review: From Zimbabwe to Azania? A Review Article". African Affairs. 82 (329): 574–578. doi:10.1093/oxfordjournals.afraf.a097565. JSTOR 721219. Prokosh, Eric, ed. (1994). "Disappearances" and Political Killings: Human Rights Crisis of the 1990s.
=== Vitamin B12-dependent enzymes === The cobalt-containing Vitamin B12 (also known as cobalamin) catalyzes the transfer of methyl (−CH3) groups between two molecules, which involves the breaking of C−C bonds, a process that is energetically expensive in organic reactions. The metal ion lowers the activation energy for the process by forming a transient Co−CH3 bond. The structure of the coenzyme was famously determined by Dorothy Hodgkin and co-workers, for which she received a Nobel Prize in Chemistry. It consists of a cobalt(II) ion coordinated to four nitrogen atoms of a corrin ring and a fifth nitrogen atom from an imidazole group. In the resting state there is a Co−C sigma bond with the 5′ carbon atom of adenosine. This is a naturally occurring organometallic compound, which explains its function in trans-methylation reactions, such as the reaction carried out by methionine synthase.
However, most colonies in Africa, even those rich in natural resources, experienced difficulty in achieving similar rates of development due to a shortage of technical and managerial skills. Small, rotating cadres of colonial civil servants who possessed little incentive to invest their skills in the local economy were insufficient to compensate for this disadvantage. Southern Rhodesia had negated the issue by importing a skilled workforce directly from abroad in the form of its disproportionately large European immigrant and expatriate population. For example, in 1951 over 90% of white Southern Rhodesians were engaged in what the British government classified as "skilled occupations", or professional and technical trades. This made it possible to establish a diversified economy with a strong manufacturing sector and iron and steel industries, and circumvent the normal British protectionist policy of supporting domestic industry in the metropole while discouraging industry in the colonies abroad. As the white population increased, so did capital imports, especially in the wake of the Second World War. This trend, too, stood in sharp contrast to most other colonial territories, which suffered a major capital deficit due to revenues simply being repatriated to the metropole, leaving little capital to be invested locally. The considerable investment made by white Rhodesians in the economy financed the development of Southern Rhodesia's export industries as well as the infrastructure necessary to integrate it further with international markets.
Sources: en.wikipedia.org
==== Reptiles ==== In larger animals, different muscle groups will increasingly require different fiber type proportions within muscle for different purposes. Turtles, such as Trachemys scripta elegans, have complementary muscles within the neck that show a potential inverse trend of fiber type percentages (one muscle has high percentage of fast twitch, while the complementary muscle will have a higher percentage of slow twitch fibers). The complementary muscles of turtles had similar percentages of fiber types.
On July 1, 2026, it was reported that Markwayne Mullin, the Secretary of Homeland Security at that time, held an investment "worth as much as $1 million in Botanic Tonics, which could benefit from the new restrictions by facing less competition in the kratom market".
Many of his reports, which he wrote primarily for the newspaper Frankfurter Allgemeine Zeitung, the news magazine Der Spiegel and the weekly newspaper Die Zeit, were also published in expanded versions as books, becoming bestsellers. In cooperation with the Avicenna relief organization founded by his father Djavad Kermani, Kermani initiated fundraising campaigns for aid projects in Aceh (Indonesia), Lesbos, Madagascar and Tigray after returning from his reporting trips. Kermani's books have been translated into numerous languages. In his public statements and speeches, Kermani regularly comments on issues of society, politics and religion. Jan-Werner Müller described him in the New York Review of Books as one of Germany's most thought-provoking intellectual voices. From 2009 to 2012, Kermani was a senior fellow at the Kulturwissenschaftliches Institut (KWI) Institute for Advanced Humanities Study in Essen. In 2009, he was appointed a corresponding member of the Akademie der Wissenschaften [Academy of Sciences] in Hamburg. In the summer semester of 2010, Kermani served as guest lecturer in poetics at the Goethe University Frankfurt, where he gave the Frankfurter Poetikvorlesungen [Frankfurt Poetics Lectures], which were later published as a book entitled Über den Zufall. Jean Paul, Hölderlin und der Roman, den ich schreibe [On Contingency: Jean Paul, Hölderlin, and the Novel I Am Writing]. In the winter semester of 2011/12, Kermani delivered the Göttingen Poetics Lecture series, and in 2014, the Mainz Poetics Lecture series.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.